【藥品訊息】 Anoro Ellipta 55/22 吸入劑 衛教單張

氣喘或慢性阻塞性肺病 Maintenance treatment of airflow obstruction in patients with COPD

Umeclidinium,  a long-acting anticholinergic, competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M3) receptors in bronchial smooth muscle causing bronchodilation. Vilanterol: LABA, stimulation of intracellular adenyl cyclase. Increased cyclic AMP levels cause relaxation of bronchial smooth muscle; inhibition of release of mediators of immediate hypersensitivity from cells.

Umeclidinium and Vilanterol : mostly absorbed from the lung after inhaled doses. Tmax, Inhalation: 5 to 15 minutes (umeclidinium and vilanterol); Elimination Half Life: Umeclidinium, 11 hurs; Vilanterol, 11 hurs. 

Severe hypersensitivity to milk proteins; hypersensitivity to umeclidinium, vilanterol, or any of the excipients. 

C

Not known

Pharyngitis, Sinusitis, Lower respiratory tract infection, Constipation, Diarrhea, Pain in extremity, Muscle spasms, Neck pain, Chest pain

ANORO ELLIPTA (umeclidinium/vilanterol 55 mcg/22 mcg) (delivered dose), 1 inhalation once daily by the orally inhaled route only.